Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

MediWound (MDWD) EBITDA (2016 - 2025)

Historic EBITDA for MediWound (MDWD) over the last 13 years, with Q3 2025 value amounting to -$2.7 million.

  • MediWound's EBITDA rose 7413.74% to -$2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year increase of 13905.96%. This contributed to the annual value of -$30.2 million for FY2024, which is 34905.63% down from last year.
  • Per MediWound's latest filing, its EBITDA stood at -$2.7 million for Q3 2025, which was up 7413.74% from $13.3 million recorded in Q2 2025.
  • In the past 5 years, MediWound's EBITDA registered a high of $13.3 million during Q2 2025, and its lowest value of -$10.3 million during Q3 2024.
  • Over the past 5 years, MediWound's median EBITDA value was -$3.2 million (recorded in 2021), while the average stood at -$2.0 million.
  • Data for MediWound's EBITDA shows a peak YoY increase of 58810.04% (in 2024) and a maximum YoY decrease of 37003.2% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows MediWound's EBITDA stood at -$4.2 million in 2021, then crashed by 80.0% to -$7.5 million in 2022, then skyrocketed by 76.54% to -$1.8 million in 2023, then plummeted by 122.58% to -$3.9 million in 2024, then surged by 31.84% to -$2.7 million in 2025.
  • Its EBITDA stands at -$2.7 million for Q3 2025, versus $13.3 million for Q2 2025 and -$725000.0 for Q1 2025.